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ABSTRACT 
Diabetic peripheral neuropathy (DPN) is one of the most common diabetic complications. 
Mechanisms underlying nerve damage and sensory loss following metabolic dysfunction 
remain large unclear. Recently, hyperglycemia-induced mitochondrial dysfunction and the 
generation of ROS have gained attention as possible mechanisms of organ damage in 
diabetes. Hypoxia-inducible factor 1 (HIF1) is a key transcription factor activated by 
hypoxia, hyperglycemia, nitric oxide as well as ROS, suggesting a fundamental role in DPN 
susceptibility. Genetically-modified mutant mice, which conditionally lack HIF1 in peripheral 
sensory neurons (SNS-HIF1α-/-), were analyzed longitudinally up to 6 months in the 
streptozotocin (STZ) model of type1 diabetes. Behavioral measurements of sensitivity to 
thermal and mechanical stimuli, quantitative morphological analyses of intraepidermal nerve 
fiber density and measurements of reactive oxygen species (ROS) in sensory neurons in 
vivo were undertaken over several months post-STZ injections to delineate the role of HIF1 
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in DPN. Longitudinal behavioral and morphological analyses at 5, 13 and 24 weeks post-
STZ treatment revealed that SNS-HIF1α-/- developed stronger hyperglycemia-evoked losses 
of peripheral nociceptive sensory axons associated with stronger losses of mechano- and 
heat sensation with a faster onset than HIF1αfl/fl mice. Mechanistically, these 
histomorphologic and behavioral differences were associated with significantly higher level 
of STZ-induced production of ROS in sensory neurons of SNS-HIF1α-/- mice as compared 
with HIF1αfl/fl. Our results indicate that HIF1 is as an upstream modulator of ROS in 
peripheral sensory neurons and exerts a protective function in suppressing hyperglycemia-
induced nerve damage by limiting ROS levels. HIF1 stabilization may be thus a new 
strategy target for limiting sensory loss, a debilitating late complication of diabetes. 
KEY MESSAGES 
 Impaired Hypoxia-inducible factor 1α (HIF1α) signaling leads to early onset of STZ-
induced loss of sensation in mice 
 STZ-induced loss of sensation in HIF1α is associated with loss of sensory nerve fiber 
in skin. 
 Activation of HIF1α signaling in diabetic mice protects the sensory neurons by 
limiting ROS formation generated due to mitochondrial dysfunction. 
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INTRODUCTION 
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Diabetes is a chronic progressive metabolic disease characterized by elevated levels of 
blood glucose. It is one of the largest health care problems worldwide, with more than 422 
million diabetic patients 1. Diabetic peripheral neuropathy (DPN) is one of the most 
common diabetic complications. Patients with DPN experience pain, tingling, prickling 
sensations and numbness, which can progress to complete loss of sensation and motor 
dysfunction. These late diabetic complications in combination with vascular damage are the 
leading cause of lower extremity amputations 2, 3. Clinical research from last two decades 
indicates that rigorous control of glucose reduces the incidence of DPN, suggesting a major 
role for hyperglycemia 4. 
Uncovering molecular mechanisms underlying DPN remains a major challenge and a lack of 
mechanistic understanding has long hampered effective therapy of DPN. Only recently, 
hyperglycemia-induced mitochondrial dysfunction and the subsequent generation of ROS 
have gained attention as possible mechanisms 5. Prolonged hyperglycemia energizes 
activation of the polyol 6, and hexosamine pathways 7, activation of PKC isoforms 8 and 
production of advanced glycation end products (AGE) 9, 10, thereby cumulatively 
increasing the intracellular ratio of NADH/NAD+. It has been hypothesized that this depletion 
of cellular antioxidant potential leads to cellular damage, which is marked by the progression 
of DPN 11. Hyperglycemia-induced ROS formation causes the development of a 
pseudohypoxia state, which modulates intracellular signaling pathways such as mitogen 
activation protein kinases (MAPKs), nuclear factor kappa B (NF-B), activator protein I (AP-I) 
and importantly, hypoxia-inducible factor-1 (HIF-1) 12, 13. 
HIF1 is a heterodimeric transcriptional factor composed of  and  subunits (HIF1 and 
HIF1 respectively) 14, 15. HIF1 is an oxygen-sensitive subunit and its activity is tightly 
regulated by cellular oxygen concentration 15, while HIF1 is constitutively expressed. In 
conditions of normoxia, HIF1 is subjected to oxygen-dependent hydroxylation at two prolyl 
residues, which enables its binding to Hippel-Lindau protein (VHL) leading to 
polyubiquitination and subsequent proteasomal degradation 16, 17. In contrast, under 
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hypoxic conditions, hydroxylation of HIF1 is inhibited, resulting in accumulation of HIF1 
and its heteromerization with HIF1. In consequence, stabilized transcription factor HIF1 
binds to hypoxia response elements (HREs) and regulates the expression of target genes, 
leading to biological consequences.  
In contrast to the clarity on hypoxia-mediated modulation of HIF1, the role of hyperglycemia 
in the modulation of HIF1 is subject to much debate. Previous studies report contradictory 
observations, e.g. hyperglycemia-induced stabilization of HIF1 in pancreatic cancer cells 
versus its inhibition in primary dermal fibroblasts 33, 45. Moreover, there is no knowledge 
on the role of HIF1 in hyperglycemia-induced dysfunction in peripheral sensory neurons in 
the course of DPN. Recently, it was reported that HIF1 deletion results in exaggerated 
acute thermal and cold nociception 18 in naïve mice, suggesting that HIF1 activity is 
important in peripheral nociceptive neurons. However, to date, the role of HIF1 in 
pathological DPN-related structural and functional changes in peripheral sensory neurons 
has not been studied. 
Here, we investigated the role of HIF1 in peripheral pain-sensing (nociceptive) neurons 
over the chronic progression of DPN in mice genetically lacking HIF1 conditionally in the 
dorsal root ganglia (DRG) by undertaking detailed longitudinal analyses spanning 6 months 
following induction of type1 diabetes in the streptozotocin (STZ) model. Our results uncover 
a previously undescribed protective role of HIF1 in nerve damage and sensory loss 
associated with chronic stages of DPN and lead to the surprising observation that HIF1 is 
an upstream modulator of ROS levels and oxidative stress in peripheral sensory neurons 
under diabetic conditions. 
 
MATERIAL AND METHODS: 
Animal experiments 
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Age-matched 7-9 wks old SNS-HIF1α-/- and HIF1αfl/fl mice were used for experiments. 
Animals were maintained in a temperature controlled room with a light/dark cycle (12/12). 
Four to five littermates were housed in individually ventilated cage-rack system (Techniplast, 
Italy) with free access to water and food. All animal experiments were done in accordance 
with ethical guidelines and approved by Regierungspräsidium Karlsruhe, Germany. 
 
Sensory-neuron-specific knockout mice 
Mice lacking HIF-1α (SNS-HIF1α-/-) in a sensory neuron-specific manner were described 
previously 18. Briefly, mice carrying homozygous alleles of HIf1α gene (HIF1αfl/fl) were 
mated with mice expressing the Cre recombinase selectively in nociceptors (SNSCre) 19 to 
obtain homozygous SNS-HIF1α-/- and HIF1αfl/fl (control littermates). We have previously 
described the basic characterization of these mice in the study by Kanngiesser et al 18. 
Rodent model of type 1 diabetic model 
Diabetes was induced by low dose multiple injections of STZ (60 mg/kg/d) in citrate buffer, 
intraperitoneally (i.p), in 8 wks-old SNS-HIF1α-/- or HIF1αfl/fl mice for 5 consecutive days. 
Blood glucose levels were measured once weekly using a glucometer (Accu-Chek, Roche 
Diagnostics) for the entire course of the experiment. Mice above > 350 mg/dl were 
considered to be diabetic. Mice were analyzed over a period of 5 wks to 24 wks post-STZ 
injection. At 2 weeks (wks) post-STZ injection, we achieved blood glucose between 380 and 
500 mg/dl. The blood glucose levels were maintained in a range between 380 and 480 mg/dl 
by administering insulin sub-cutaneously as required over the entire course of an experiment 
to ensure uniformity and consistency. 
 
Behavioral measurements 
All behavioral experiments were done in awake, unrestrained, acclimatized, age-matched 
adult mice. Mice were habituated to the experimental setup twice a day for 4 days prior to 
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the behavioral testing. The experimenter was blinded for the genotype of the groups tested 
in the experiment. Thermal sensitivity was measured by recording paw withdrawal latency on 
application of infrared (IR) heat source on the plantar surface of hindpaw. A cut off of 20 sec 
was set to avoid burning of tissue. Two consecutive heat applications are performed at a 
time interval of 5 minutes. Von Frey measurements were done to assess mechanical 
sensitivity as described previously 20. Briefly, mice were placed on an elevated grid and 
von Frey monofilaments exerting a specific force of 0.07, 0.16, 0.4, 0.6, 1.0, 1.4, 2.0 and 4.0 
g were tested on the plantar hindpaw. Each monofilament was applied for 5 times at time 
interval of 5 min on the plantar hindpaw. 60% response frequency was as “thresholds” as 
described previously at basal, 14 and 24 wks post-STZ injection. 
 
ROS measurements in DRG 
To detect production of ROS and superoxide in DRG of SNSHIF1α-/- and HIF1αfl/fl diabetic 
and nondiabetic mice, we intrathecally (i.t) injected MitoTrackerRedCM-H2XROS dye (100 
nm, 10 µl, Life Technologies). Twenty four h later, mice were perfused with 1x PBS and 4% 
PFA and DRG were extracted and 16 µm sections were made on cryotome 21. The dye is 
in reduced form and non-fluorescent in the basal state and becomes fluorescent upon 
oxidation 22. Presence of MitoTrackerRedCM-H2XROS fluorescence at different point of 
time point’s post-STZ injection was analyzed using confocal microscopy. 
 
Immunohistochemistry 
Immunohistochemistry was performed on punch biopsies of the plantar surface of the 
hindpaws in diabetic and non-diabetic HIF1αfl/fl an SNS-HIF1α-/- mice prior to and different 
time points post-STZ. The mice were perfused with 4% paraformaldehyde (PFA) and plantar 
skin was post-fixed in 4 % PFA for 24 hrs at 4°C. After overnight incubation in 30% sucrose, 
16 µm cryo sections were made. The sections were permeabilized in 0.5% PBST, washed 
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and blocked with 7% Horse serum (HS). The sections were incubated overnight with anti-
CGRP (1:1000, sigma) primary antibody in 7% HS in PBS at 4°C 23. Subsequently, 
sections were washed and incubated in Alexa Fluor-594-conjugated secondary antibody. 
Further, the sections were washed and mounted in Mowiol. Fluorescence images were 
obtained using a laser-scanning spectral confocal microscope and maximal projections were 
created using Leica SP8 software (Leica TCS SP8 AOBS, Bensheim, Germany). Same 
conditions were used for imaging of sections from control and test groups. The acquired 
images were analyzed using ImageJ software. The fluorescence intensity from the epidermal 
area was measured and the background staining from IgG control was deducted from each 
test sample.  
 
Statistical analysis 
All the data were calculated and are presented as mean ± SEM. ANOVA for repeated 
measures followed by Bonferroni’s test for multiple comparisons was employed to determine 
statistically significant differences. Changes with p ≤ 0.05 were considered to be significant. 
 
RESULTS 
In vivo modulation of nociception by HIF1α in STZ model of type 1 diabetes 
This study investigated the role of HIF1α in the modulation of levels of ROS in dorsal root 
ganglia in diabetic and non-diabetic mice. In order to address a potential contribution of 
HIF1 to DPN, we employed a mouse line with conditional genetic loss of HIF-1α selectively 
in a sensory neuron-specific manner (SNS-HIF1α-/- mice 18, 19. In this line, we have 
previously demonstrated the deletion of HIF1 in peripheral nociceptive neurons via 
quantitative RT-PCR and in situ hybridization 18. The STZ model of type 1 is characterized 
by slowly progressive  cell death and subsequently lymphocytic infiltration of pancreatic 
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islets 26. To investigate the role of HIF-1α in diabetes-induced ROS modulation, we 
employed a protocol of STZ injections, which gradually induces hyperglycemia and 
precludes acute neurotoxic effects that may result from high doses of STZ 24, 25. Using 
this protocol, hyperglycemia developed to comparable levels in SNS-HIF1α-/- and HIF1αfl/fl 
mice (Fig 1a). Behavior measurements in STZ-injected mice are an important and direct 
measure of the progression of DPN. The STZ protocol reproduces sensory phenomena of 
human DPN, i.e. hyperalgesia, which is evident over 5-8 weeks post-STZ, and progressive 
loss of sensory functions, which is evident starting 20 wks post-STZ injection 27, 28. We 
performed long-term studies in SNS-HIF1α-/- and corresponding control mice (HIF1αfl/fl) in the 
STZ model to determine the course of behavioral changes, setting a focus on 5, 13 and 24 
wks post-STZ injection. Thus, the time points we chose are temporally separated from 
potential acute toxic effects of STZ.  
At 5 wks post-STZ, we observed that both SNS-HIF1α-/- and HIF1αfl/fl develop similar levels 
of hypersensitivity to mechanical stimuli applied to plantar surface of paw in form of graded 
strength von Frey hairs, evident as a decrease in mechanical nociceptive thresholds (figure 
1b, c). Similarly, the development of thermal hyperalgesia, which is evident as a decrease in 
latency to an infrared heat lamp applied to the hindpaw plantar surface (figure 1b, c). In 
contrast, at 13 and 24 wks post-STZ injection, deletion of HIF1α in sensory neurons of the 
DRG had a marked impact on the development of sensory losses. Upon measuring 
mechanical response thresholds at 13 and 24 wks post-STZ, we observed that SNS-HIF1α-/- 
showed hypoalgesia as compared to HIF1αfl/fl mice, indicating an increase in the magnitude 
of STZ-induced sensory losses (figure 1b,*, #  p<0.0001, ANOVA, Bonferroni’s test). 
Similarly, in the Hargreaves test, the time required for paw withdrawal upon stimulation with 
radiant heat was significantly increased in STZ-treated SNS-HIF1α-/- mice as compared to 
STZ-treated HIF1αfl/fl mice (figure 1c, * p<0.05, *** p<0.0001, # p<0.01, ANOVA, Bonferroni’s 
test). Hence, SNS-HIF1α-/- mice developed faster onset of hypoalgesia and thus showed a 
stronger loss of sensory function as compared to control mice, which is an indicative of an 
accelerated course of DPN upon loss of HIF1α specifically in peripheral sensory neurons. 
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Manifestation of DPN in SNS-HIF1α-/- mice post-STZ injection 
In order to complement behavioral abnormalities with actual changes in nerve morphology, 
we conducted a detailed neuropathological analysis of changes in epidermal nerve fiber 
density. We performed immunostaining of markers for nociceptive nerves, such as Calcitonin 
Gene-Related Peptide (CGRP), on skin sections in a longitudinal analysis up to 24 wks post-
STZ. We analyzed DPN-associated reductions in the density of epidermal nociceptive 
innervation, measured by the fluorescence intensity of CGRP-positive fibers in epidermal 
region of the glaborous skin derived from the paw. The magnitude of this loss was higher 
and the progression faster in SNS-HIF1a-/- mice as compared to HIF1αfl/fl mice (Fig. 2a, b, * 
p<0.0001, # p<0.01, ANOVA, Bonferroni’s test), at 13 and 24 wks post-STZ injection, 
indicating an aggravation of DPN manifestations in the absence of HIF1α. 
 
Modulation of ROS levels in DRGs of diabetic mice by HIF1α 
Previous studies have established that hyperglycemia modulates the respiratory chain of the 
mitochondria and augments oxidative stress 29. Overproduction of ROS has been shown 
to modulate HIF1 function 30, with both positive and negative modulation being reported, 
and several mechanisms have been proposed 31, 32, 16. Despite these insights on the 
regulation of HIF1 by ROS, none of the studies investigated the impact of HIF1 function on 
modulation of ROS levels itself. Therefore, we measured the levels of ROS in vivo in DRG 
neurons of SNS-HIF1α-/- and control HIF1αfl/fl mice in the basal state (i.e. naïve mice) and at 
13 or 24 wks post-STZ treatment. We intrathecally injected MitoTrackerRedCM-H2XROS 
(100 nm, 10 µl), a reporter for ROS generation 22, and observed that STZ-induced DPN 
was linked to a significant increase in MitoTrackerRedCM-H2XROS fluorescence in DRG 
neurons, suggesting ROS and superoxide build-up (Fig. 3a, b, *, # p<0.0001, ANOVA, 
Bonferroni’s test). Importantly, the extent of ROS and superoxide accumulation was 
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significantly increased in SNS-HIF1α-/- mice as compared to HIF1αfl/fl mice at 13 and 24 wks 
of STZ injection (Fig. 3a, b). Thus, a selective deletion of HIF1α resulted in inflated levels of 
ROS formation in peripheral sensory neurons in vivo at time points, which temporally 
matched the exacerbation of DPN in SNS-HIF1α-/- mice. 
 
DISCUSSION 
The main insights revealed by this study are: (i) the transcription factor HIF1α plays a 
protective role against axonal pathology and loss of peripheral nerve fibers in DPN, (ii) a loss 
of HIF1α in sensory neurons of diabetic mice leads to a faster progression of DPN-
associated loss of sensation at the level of organismal behavior; (iii) a loss of HIF1α results 
in an enhanced build-up of ROS in sensory neurons, thereby placing ROS downstream of 
HIF1α. 
 
HIF1α has only recently been suggested to modulate pain following direct mechanical injury 
to peripheral nerves 18. However, to date, nothing was known about the role of HIF1α in 
pain and nerve damage caused by metabolic dysfunction. Indeed, there is a large 
mechanistic diversity between diverse forms of pathological pain, such as that arising from 
direct mechanical injury to nerves that is focal and localized versus metabolically-induced 
nerve dysfunction in the course of diabetes, which is widespread and diffuse. Very little is 
known about how nerve damage develops under metabolic stress. We hypothesized that 
HIF1α may be a vital link because it has been reported to be directly regulated by 
hyperglycemia in some tissues, such as endothelial cells and cardiac myocytes, with both 
positive and negative modulation being reported 33. Indeed, using highly selective genetic 
perturbations, we observed that both structural remodeling of nerves and their functionality 
(via behavioral analysis) were highly affected upon a loss of HIF1α in sensory neurons. 
Interestingly, only chronic changes, such as structural damage and the ensuing sensory loss 
at about 4-6 months post-diabetes induction were affected in SNS-HIF1α-/- mice, 
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emphasizing the strength of longitudinal analyses. Particularly this late component of 
diabetic changes is key in the clinical situation, frequently resulting in small and large fiber 
neuropathies, diabetic feet and amputations 34. In contrast, early STZ-evoked 
hypersensitivity was not changed upon a loss of HIF1α in sensory neurons. Several recent 
studies have addressed mechanisms of early hyperalgesia in diabetic models and there is 
converging evidence that this involves acute modulation of ion-channels, such as members 
of the Transient Receptor Potential (TRP) family, such as TRPV1 and TRPA1 by oxidative or 
lipid metabolites 35, 36. 
 
The nature of modulation of DPN by HIF1α is of much interest. In terms of injury induced by 
hypoxia and/or hyperglycemia, both protective and destructive roles have been observed for 
HIF1α depending upon the type of tissue and the context 33, 37. Here, we observed a 
protective function for HIF1α against nerve damage induced by metabolic dysfunction in a 
model of type 1 diabetes. These observations were further strengthened by measurement of 
ROS levels in DRG, which revealed that the deletion of HIF1α results in increased 
accumulation of ROS in sensory neurons as compared to controls over chronic phases of 
diabetes. This is unexpected, because previously published studies in other tissues reported 
the modulation of HIF1 activity by ROS, but there is little evidence for modulation of ROS 
levels by HIF1. In kidney tissue under hyperglycemia conditions, ROS has been shown to 
impair HIF1α activation as well as expression via inhibition of NO and Rac1 33. Moreover, 
ROS can further inhibit HIF1α by increasing ubiquitin-proteasome activity 38. In contrast, 
Bonello et. al. demonstrate that ROS leads to HIFα expression and activation in a NFB-
dependent manner in pulmonary artery smooth muscle cells 39. In sensory neurons of 
chronically hyperglycemic mice, we observed that ROS is downstream of HIFα, which 
suggests that HIFα exerts its neuroprotective functions in this context by suppressing ROS. 
The precise mechanisms how HIFα affects ROS levels are not clarified in this study. 
Contributing mechanisms may include the role of HIF1 in modulating the expression of 
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metabolic enzymes 40, which may decrease the metabolic overload in sensory nerves and 
suppress the generation of harmful ROS and free radical species. 
 
Recent studies have implicated ROS in the modulation of acute pain 41 and the 
administration of ROS scavengers peripherally or spinally has antinociceptive effects in 
models of inflammatory and neuropathic pain 42. It is believed that ROS production via 
mitochondrial respiratory chain is a causal link between hyperglycemia and pathways 
involved in hyperglycemia-induced tissue damage. Under hyperglycemic conditions, the 
increased electron flux in the respiratory chain leads to an increase in the ATP/ADP ratio 
and in the mitochondrial membrane potential, which result in partial inhibition of complex III 
and thereby induce an accumulation of electrons to generate potentially harmful complex-I 
ROS 29, 43. It is postulated that accumulation of ROS may result in a bioenergetic failure, 
depletion of antioxidant defenses and neuroinflammation 44. These mechanisms likely 
contribute to nerve damage and the ensuing sensory loss observed upon the excessive 
accumulation of ROS in diabetic mice lacking HIF1. 
 
CONCLUSIONS 
In summary, this study identifies HIF1 as an important protective molecule against DPN-
associated long-term nerve damage and sensory loss. Moreover, we propose that HIF1α 
functions as an upstream suppressor of ROS levels in sensory neurons. These observations 
have direct relevance to a highly debilitating and intractable long-term complication of 
diabetes and hold significance for novel therapeutic measures designed to strengthen the 
protective role of HIF1 in sensory neurons over chronic diabetes.  
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Figure legends: 
Figure 1: Analysis of hyperglycemia and sensory dysfunction in mice lacking HIF1α 
selectively in peripheral nociceptive neurons (SNS-HIF1α-/-) in the Streptozotocin (STZ) 
model of type 1 diabetes in a longitudinal study spanning 6 months. (A) Blood glucose levels 
in SNS-HIF1α-/- and HIF1αfl/fl mice after STZ injection (B & C) Course of DPN-associated 
sensory changes upon loss of HIF1α in peripheral nociceptive neurons. (B) Summary of 
response thresholds to mechanical stimuli (defined as a force eliciting a response of paw 
withdrawal at least 40% response rate) and (C) thermal latency before and at 5, 13 and 24 
days after STZ treatment (60 mg/kg for 5 days) in SNS-HIF1α-/- or HIF1αfl/fl (n = 10 mice per 
group). Data are represented as mean ± S.E.M. *p < 0.05 compared to baseline, # p < 0.05 
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as compared to control group two-way ANOVA for repeated measurements with Bonferroni 
multiple comparison test.  
 
Figure 2: Course and quantitative morphological analysis of DPN-associated pathology of 
peripheral nociceptive nerves in SNS-HIF1α-/- mice and control littermates. (A) Identification 
of intra-epidermal nerve fibers via immunostaining for CGRP in the paw skin of SNS-HIF1α-/- 
and HIF1αfl/fl mice after STZ injection. The dotted white lines represent the epidermal layer in 
the skin. (B) Quantification of reduction in epidermal nerve fiber density post-STZ injection in 
SNS-HIF1α-/- and HIF1αfl/fl mice. n=6 - 8 mice per group. Data are represented as mean ± 
S.E.M. *p < 0.05 compared to baseline, # p < 0.05 as compared to control group two-way 
ANOVA for repeated measurements with Bonferroni multiple comparison test. Scale bar 
represents 30 µm. 
Figure 3: Quantitative analysis of ROS measurement in vivo in peripheral sensory neurons 
at stages corresponding to chronic nerve damage and sensory dysfunction in diabetic mice. 
(A) Examples and (B) quantitative analysis of MitoTrackerRed staining in DRGs of STZ-
injected SNS-HIF1α-/- and HIF1αfl/fl mice after intrathecal delivery of the ROS reporter dye. 
Arrows indicate ROS-positive neurons; n=6 DRGs per group.  *p < 0.05 compared to 
baseline, # p < 0.05 as compared to control group two-way ANOVA for repeated 
measurements with Bonferroni multiple comparison test. Scale bar represents 30 µm. 
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